Ipratropium Bromide Aurobindo (Ipratropium Bromide)

Ipratropium bromide is an anticholinergic bronchodilator used in the management of obstructive airway diseases.

• Chronic obstructive pulmonary disease (COPD): improves airflow and reduces exacerbations.
• Asthma: provides additional bronchodilation as a maintenance therapy.
• Bronchospasm associated with COPD: relieves acute bronchoconstriction episodes.

• Ipratropium bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3) on airway smooth muscle and submucosal glands. By blocking acetylcholine‑mediated bronchoconstriction, it reduces airway resistance and secretions, leading to bronchodilation and improved ventilation in obstructive lung conditions. The effect is localized to the respiratory tract due to limited systemic absorption after inhalation.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and related to its anticholinergic activity.

Common Side Effects

• Dry mouth: reduced salivary secretion.
• Cough: irritation of the airway.
• Throat irritation: discomfort in the throat.
• Headache: mild to moderate.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing.
• Angioedema: swelling of face, lips or tongue.
• Severe allergic reaction: rash, hives, or anaphylaxis.

When prescribing or dispensing ipratropium bromide, consider the following precautions to ensure safe use.

• Assess renal function: dose may need adjustment in severe impairment.
• Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision.
• Use caution in narrow‑angle glaucoma: anticholinergic action can increase intra‑ocular pressure.
• Avoid in patients with urinary retention: may exacerbate difficulty voiding.
• Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Other inhaled anticholinergics (e.g., tiotropium): risk of excessive anticholinergic burden.
• Systemic anticholinergic drugs (e.g., atropine): may increase anticholinergic side effects.

Moderate Interactions (Monitor Closely)

• Beta2‑agonists (e.g., albuterol): additive bronchodilation may require monitoring.
• Theophylline: possible increase in plasma levels; monitor therapeutic range.
• Inhaled corticosteroids: no major interaction but monitor overall respiratory status.